1. Generics Bulletin
  2. >>Products

England Expects Biosimilar Savings Of Up To Half A Billion

 
• By Aidan Fry

With a tender and reference prices for adalimumab now in place, NHS England has raised its forecast for annual savings through biosimilar competition to half a billion pounds.  

Currency
Savings to england's National Health Service through biosimilar competition could run to £500m a year • Source: Shutterstock

England’s National Health Service (NHS) now believes the competition brought about by biosimilars could save it up to £500m ($636m) annually within the next year or so. That figure is roughly double what the health system was forecasting barely 18 months ago, before a highly competitive, multisource market for adalimumab developed.

A revised guidance document on ‘What is a biosimilar medicine

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

More from Products

Tetris Deal Falls Into Place For UK’s Aspire

 
• By Dave Wallace

Niche generics company Aspire Pharma has struck a deal to acquire a portfolio of products from fellow UK firm Tetris Pharma as it is wound up, paying Tetris parent Arecor £0.5m for UK distribution rights and inventory.

Apotex Extends Formosa Ophthalmic Alliance Into Mexico

 
• By Dave Wallace

Apotex has expanded an alliance formed with Formosa in August for its novel clobetasol propionate ophthalmic treatment, adding Mexican rights to its existing deal for the Canadian market.

Fresenius Kabi Lauds Tocilizumab Momentum As ‘Intense’ Transfer To mAbxience Continues

 
• By Dean Rudge

Fresenius Kabi continued to reap the rewards of its fledgling commercial Biopharma business in the first quarter, as the firm eyes further growth for its tocilizumab biosimilar in the US and Europe in the second half of 2025.